This site is intended for healthcare professionals

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. will commercialise mirvetuximab soravtansine in mainland China, Hong Kong, Macau, and Taiwan. -ImmunoGen.

Read time: 1 mins
Last updated:16th Mar 2021
Published:20th Oct 2020
Condition: Ovarian Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest